verinurad
Small moleculeexperimental
Clinical trial activity
22 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
14
Phase 2
9
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01872832)
Timeline
Indications
Mechanism of action
- Solute carrier family 22 member 12INHIBITOR
Solute carrier family 22 member 12 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CC(C)(Sc1ccncc1-c1ccc(C#N)c2ccccc12)C(=O)O- Mol. weight
- 348.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3707347 ↗
Also known as
- rdea3170
- rdea3170
- verinurad
- verinurad
- verinurad
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04550234 | Phase 1 | Jul 1, 2021 | AstraZeneca, Parexel |
| NCT04532918 | Phase 1 | Sep 10, 2020 | AstraZeneca, Parexel |
| NCT04327024 | Phase 2 | Apr 15, 2020 | AstraZeneca |
| NCT04256629 | Phase 1 | Feb 26, 2020 | AstraZeneca, Parexel |
| NCT03990363 | Phase 2 | Jul 19, 2019 | AstraZeneca |
| NCT04024501 | Phase 1 | Jul 17, 2019 | AstraZeneca |
| NCT03836599 | Phase 1 | Jan 16, 2019 | AstraZeneca, Parexel |
| NCT03316131 | Phase 2 | Oct 25, 2017 | AstraZeneca, Covance, GenX Laboratories Inc., Parexel |
| NCT03118739 | Phase 2 | May 18, 2017 | AstraZeneca |
| NCT02608710 | Phase 1 | Nov 1, 2015 | Ardea Biosciences |
| NCT02498652 | Phase 2 | Jul 1, 2015 | Ardea Biosciences |
| NCT02448368 | Phase 1 | May 1, 2015 | Ardea Biosciences |
| NCT02317861 | Phase 1/Phase 2 (Phase 2) | Dec 1, 2014 | Ardea Biosciences, AstraZeneca |
| NCT02336594 | Phase 1 | Nov 1, 2014 | Ardea Biosciences |
| NCT02279641 | Phase 1 | Nov 1, 2014 | Ardea Biosciences |
| NCT02246673 | Phase 2 | Oct 1, 2014 | Ardea Biosciences |
| NCT02219516 | Phase 1 | Aug 1, 2014 | Ardea Biosciences |
| NCT02078219 | Phase 2 | Jan 1, 2014 | Ardea Biosciences, AstraZeneca |
| NCT01927198 | Phase 2 | Aug 1, 2013 | Ardea Biosciences |
| NCT01910506 | Phase 1 | Aug 1, 2013 | Ardea Biosciences |
Showing 20 of 22 trials
Page 1 / 2
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ardea Biosciences | For profit | 13 | 11 | 2 | 2013 |
| AstraZeneca | For profit | 11 | 11 | 2 | 2014 |
| Parexel | For profit | 5 | 0 | 2 | 2017 |
| Covance | For profit | 1 | 0 | 1 | 2017 |
| GenX Laboratories Inc. | For profit | 1 | 0 | 1 | 2017 |
5 organizations
Page 1 / 1